Pharmaceutical Technology29m
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.
Pharmaceutical Technology31m
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics’s Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
Pharmaceutical Technology38m
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies’s ITI-333?
ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.
Pharmaceutical Technology58m
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s Cendakimab?
Cendakimab is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase III program in Eosinophilic Esophagitis.
Pharmaceutical Technology33m
Risk adjusted net present value: What is the current valuation of Roche’s RG-6641?
RG-6641 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ...
Pharmaceutical Technology32m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.
Pharmaceutical Technology29m
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology39m
Risk adjusted net present value: What is the current valuation of UCB’s (Doxecitine + Doxribtimine)?
(Doxecitine + Doxribtimine) is a small molecule commercialized by UCB, with a leading Phase III program in Inherited Mitochondrial Disorders.
Pharmaceutical Technology47m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology47m
Risk adjusted net present value: What is the current valuation of Cogent Biosciences’s Bezuclastinib?
Bezuclastinib is a small molecule commercialized by Cogent Biosciences, with a leading Phase III program in Gastrointestinal Stromal Tumor (GIST).